- Tension: Two genuinely important values — protecting people from over-medicalisation and ensuring access to effective treatment — are being forced into a false opposition that leaves vulnerable people without care.
- Noise: Media coverage swings between “antidepressants are overprescribed” and “we are in a mental health crisis” without ever reconciling the two, generating heat instead of clarity.
- Direct Message: The antidepressant debate was never really about medication — it is about what we believe people in distress actually deserve.
To learn more about our editorial approach, explore The Direct Message methodology.
Watching a policy debate unfold around something you or someone you care about relies on to stay functional produces a specific kind of dread. Not the abstract dread of a news cycle, but something more personal. The feeling of watching your own life become an argument.
That is what this week’s story about antidepressants asks many people to sit with.
On May 5, U.S. Health Secretary Robert F. Kennedy Jr. announced a federal initiative to reduce what he described as the overprescribing of psychiatric medications, with a particular focus on SSRIs — selective serotonin reuptake inhibitors like Zoloft, Prozac, Lexapro, and Paxil. He spoke at a daylong Mental Health and Overmedicalization Summit hosted by the Make America Healthy Again Institute, outlining plans that include new training for healthcare providers, changes to Medicare and Medicaid billing that would reimburse clinicians for helping patients taper off medications, and federal guidance on deprescribing.
Three days later, Reuters reported that HHS officials had, in the days before the summit, explored whether they could impose a ban on certain drugs within the SSRI class. HHS denied that any such discussions had taken place. But the story had already landed.
What the research actually says
SSRIs are taken by roughly one in six U.S. adults, according to a 2026 study in BMJ Mental Health. They are, by any measure, among the most commonly prescribed medications in the country. The American Psychiatric Association considers them a first-line, evidence-based treatment for depression.
That does not mean they are uncomplicated. SSRIs carry real side effects, which can include sexual dysfunction, sleep disturbances, weight changes, and in some cases difficulty discontinuing the medication. In 2004, the FDA issued a black box warning noting a possible increased risk of suicidality in children and young adults taking antidepressants. This warning is real, and it matters. It has shaped prescribing guidelines for decades.
What it does not support is a blanket case for restricting access to the medications in adults, or treating a heterogeneous patient population as though they share a single risk profile.
What Dr. Olfson said, and why it matters
Dr. Mark Olfson, a psychiatrist at Columbia University Medical Center, offered one of the clearest responses to the policy direction.
“Although these medications carry real risks and should be prescribed thoughtfully,” he said, “abrupt policy efforts that stigmatize or limit access could produce serious public-health consequences for patients who rely on them.”
The phrasing is careful and worth reading slowly. He did not say SSRIs are without risk. He said that abrupt, stigmatizing restrictions could cause serious harm. That is a different claim, and a more precise one.
The word stigmatize is doing important work there. One of the less visible effects of public campaigns that frame antidepressant use as a dependency crisis or as evidence of overmedicalization is that they can change how people feel about seeking or continuing treatment. Not through policy but through atmosphere. Through the message, implied or stated, that being on these medications means something unflattering about you or your choices.
The framing problem
Kennedy’s language at the summit was careful in some places and less careful in others. He said explicitly that the government was not telling people who are currently taking psychiatric medication to stop. He acknowledged that psychiatric medications have a role in care.
But he also described a national “dependency crisis driven by overmedicalization.” And in prior public statements — including a 2023 campaign interview and remarks reported by Politico — he has linked SSRI use to violence and mass shootings, claims that are not supported by the peer-reviewed psychiatric literature and that major medical organizations have publicly disputed.
The American Psychiatric Association, in its response to the summit announcement, strongly objected to framing the country’s mental health crisis as primarily a problem of overprescription. Dr. Theresa Miskimen Rivera, the association’s president, called it an oversimplification that “ignores the larger reality, which is that too many patients really cannot access timely, comprehensive care.”
The FDA cannot unilaterally ban medications that have already been approved without strong new evidence that the risks to patients outweigh the benefits. Drug regulatory experts have noted that any such review process would take months to years. The legal and scientific barriers are high.
But the policy conversation, and the cultural conversation it shapes, can move faster than any regulatory process.
What the debate is really about
There is a version of this conversation that most psychiatrists and patients would welcome: better informed consent, clearer guidance on how long someone should stay on a medication and how to taper off it safely, more investment in therapy and non-pharmacological options. Several of the initiatives Kennedy announced gesture toward these aims, and they are legitimate ones.
The problem is when that conversation becomes entangled with a broader ideological claim — that the country’s mental health crisis is primarily a pharmaceutical dependency story rather than an access and structural care story. That framing tends to flatten the extraordinary variation in why people are on antidepressants. Some are managing acute depressive episodes. Some have treatment-resistant conditions that have failed every other intervention. Some have been stable on low doses for years. Policy that treats all of these people as a single category, defined primarily by the medications they take, is not precision medicine.
What gets lost in the noise
The people most affected by this conversation are often the quietest in it.
They are managing. They are going to work, or trying to. They are parenting, studying, teaching, functioning at some level they could not sustain without pharmaceutical support, or they tried stopping once and it did not go well, and they remember what that was like.
When a public debate about their medication is conducted primarily in terms of dependency crises and overmedicalization summits and hypothetical federal bans, something happens to those people that goes beyond policy. The legitimate, carefully considered, often hard-won decision they made with their doctor starts to feel like something they have to defend.
That is the public-health consequence Dr. Olfson is pointing to. Not just the abstract risk of reduced access. The quieter cost of making people who rely on these medications feel that their treatment is a problem to be solved rather than a decision to be respected.
What this moment asks of us
The question underneath all of this is not simply whether SSRIs are overprescribed, though that is worth studying carefully and honestly. The deeper question is who gets to define what normal brain chemistry looks like, who bears the cost when that definition is wrong, and what we are protecting when we make it harder for people to access treatments that help them stay here and stay well.
Those are not questions with clean policy answers. But they are worth holding more carefully than the current conversation suggests.
